COEP

Company Overview — What Does Coeptis Therapeutics Holdings, Inc. Do?

Bull Horn Holdings Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was founded in 2018 and is based in Miami Beach, Florida. Coeptis Therapeutics Holdings, Inc. (COEP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David Mehalick and employs approximately 2 people. With a market capitalization of $70M, COEP is one of the notable companies in the Healthcare sector.

Coeptis Therapeutics Holdings, Inc. (COEP) Stock Rating — Reduce (April 2026)

As of April 2026, Coeptis Therapeutics Holdings, Inc. receives a Reduce rating with a composite score of 31.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COEP ranks #3,630 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Coeptis Therapeutics Holdings, Inc. ranks #590 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

COEP Stock Price and 52-Week Range

Coeptis Therapeutics Holdings, Inc. (COEP) currently trades at $11.95. The stock lost $0.67 (5.3%) in the most recent trading session. The 52-week high for COEP is $21.41, which means the stock is currently trading -44.2% from its annual peak. The 52-week low is $6.26, putting the stock 90.9% above its annual trough. Recent trading volume was 19K shares, suggesting relatively thin trading activity.

Is COEP Overvalued or Undervalued? — Valuation Analysis

Coeptis Therapeutics Holdings, Inc. (COEP) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.63x, versus the sector average of 2.75x. The price-to-sales ratio is 129.93x, compared to 1.66x for the average Healthcare stock.

At current multiples, Coeptis Therapeutics Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Coeptis Therapeutics Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Coeptis Therapeutics Holdings, Inc. (COEP) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -87.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -76.3% versus the sector average of -33.1%.

On a margin basis, Coeptis Therapeutics Holdings, Inc. reports gross margins of 62.2%, compared to 71.5% for the sector. The operating margin is -3249.6% (sector: -66.1%). Net profit margin stands at -2918.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

COEP Debt, Balance Sheet, and Financial Health

Coeptis Therapeutics Holdings, Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.16x, indicating strong short-term liquidity. Total debt on the balance sheet is $250,000. Cash and equivalents stand at $5M.

COEP has a beta of 0.43, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Coeptis Therapeutics Holdings, Inc. is 42/100, reflecting average volatility within the normal range for its sector.

Coeptis Therapeutics Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Coeptis Therapeutics Holdings, Inc. reported revenue of $500,996 and earnings per share (EPS) of $-2.81. Net income for the quarter was $-12M. Gross margin was 62.2%. Operating income came in at $-13M.

In FY 2025, Coeptis Therapeutics Holdings, Inc. reported revenue of $1M and earnings per share (EPS) of $-2.81. Net income for the quarter was $-12M. Gross margin was 86.8%. Operating income came in at $-13M.

In Q3 2025, Coeptis Therapeutics Holdings, Inc. reported revenue of $237,441 and earnings per share (EPS) of $-0.58. Net income for the quarter was $-3M. Gross margin was 81.0%. Operating income came in at $-2M.

In Q2 2025, Coeptis Therapeutics Holdings, Inc. reported revenue of $200,681 and earnings per share (EPS) of $-1.17. Net income for the quarter was $-4M. Gross margin was 77.5%. Operating income came in at $-5M.

Over the past 8 quarters, Coeptis Therapeutics Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $500,996. Investors analyzing COEP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

COEP Dividend Yield and Income Analysis

Coeptis Therapeutics Holdings, Inc. (COEP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

COEP Momentum and Technical Analysis Profile

Coeptis Therapeutics Holdings, Inc. (COEP) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

COEP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Coeptis Therapeutics Holdings, Inc. (COEP) ranks #590 out of 838 stocks based on the Blank Capital composite score. This places COEP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing COEP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COEP vs S&P 500 (SPY) comparison to assess how Coeptis Therapeutics Holdings, Inc. stacks up against the broader market across all factor dimensions.

COEP Next Earnings Date

No upcoming earnings date has been announced for Coeptis Therapeutics Holdings, Inc. (COEP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy COEP? — Investment Thesis Summary

The quantitative profile for Coeptis Therapeutics Holdings, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 20/100 indicates premium valuation.

In summary, Coeptis Therapeutics Holdings, Inc. (COEP) earns a Reduce rating with a composite score of 31.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COEP stock.

Related Resources for COEP Investors

Explore more research and tools: COEP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COEP head-to-head with peers: COEP vs AZN, COEP vs SLGL, COEP vs VMD.